Une stratégie qui commence à payer - NEUTRE - OC 0,8€ (vs 0,9€)
La croissance forte des ventes au T2 17 (+37%) traduit les 1ers effets positifs de la réorientation stratégique. Cette publication solide devrait faire partiellement digérer la baisse significative du cours (-32%) depuis l’AK (5,6m€) de juin. Cette dernière bien que dilutive a néanmoins permis d’allonger la visibilité financière au T3 18. Une véritable revalorisation ne devrait s’effectuer que lorsque cette tendance de croissance sera inscrite durablement. Nous conservons notre estimation de ventes 2017e de 3,6m€ (+50%) bien qu’exigeante. OC abaissé à 0,8€ vs 0,9€ préc. pour intégrer une dilution plus forte qu’escompté de la prochaine AK suite à la baisse du cours. NEUTRE maintenu.Safe Orthopaedics SAS. Safe Orthopaedics SA is a France-based company principally engaged in the medical devices industry. The Company focuses on the development and commercialization of products for use in spinal surgery. It provides a range of implants and ready to use instrument kits. The Company's product portfolio comprises SteriSpine PS, which is the Pedicle Screw System; and SteriSpine LC, which is the Lumbar Cage System that enables safe implant positioning, as well as access, insertion and placement of the implant. The Company's products are equipped with quick change handle, dual trial and impact removal, among others. The Company mainly uses polyarylamid material, which is a polymar with 50% glass fibers.
Since 2006, Invest Securities has become one of the leading players in investment services for funds and managers, to whom we offer a global and personalised service. Our track record differentiates us and proves our leadership in numerous promising sectors like property and growth companies.
Consisting of 13 different profiles (pharmacist, engineer, financier, etc), the DNA of our financial analysis office is value added and sector expertise. Through daily monitoring and detailed analyses of companies and sectors, we seek to provide a differentiating vision of our 120 stocks followed. Our ideas are circulated every day to nearly 1,000 professionals.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.